ELUTIA INC.

Elutia Inc. (Nasdaq Capital Market: ticker symbol not specified in cover page) operates through its website at https://investors.Elutia.com and develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company's mission centers on humanizing medicine so patients can thrive without compromise, with a focus on addressing unmet medical needs and reducing complications associated with surgery, including infection, migration, erosion, implant rejection, and fibrosis.

The company operates through two primary reportable segments: Women's Health and Cardiovascular. The Women's Health segment markets SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction, particularly in breast reconstruction procedures. The Cardiovascular segment comprises ProxiCor, VasCure, and Tyke products, which are derived from porcine small intestinal submucosa extracellular matrix and cleared for various cardiac and vascular repair applications.

Elutia's core strategy involves advancing its drug-eluting biomatrix platform, with lead development programs comprising NXT-41 and NXT-41x, next-generation biologic scaffolds combined with local antibiotic delivery designed for reconstructive surgery applications. The company expects FDA clearance of NXT-41 in the second half of 2026 and anticipates clearance for NXT-41x by mid-2027.

In October 2025, Elutia divested its Device Protection segment through the sale of its cardiac implantable electronic device business, including EluPro and CanGaroo products, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million in cash. Previously, in November 2023, the company sold its Orthobiologics Business to Berkeley Biologics, LLC for approximately $14.6 million with potential earn-out payments up to $20 million.

The company maintains approximately 26,598 square feet of production, laboratory, and administrative space in Gaithersburg, Maryland, serving as its headquarters and primary operations site, with an additional corporate office in San Diego, California. Elutia sells its products through independent sales agents primarily in the United States market. The company relies on third-party suppliers, including Berkeley for SimpliDerm and Cook Biotech for cardiovascular product materials, maintaining exclusive or sole-source supply relationships for certain critical materials.